Diagnostic And Treatment Methods For Ulcerative Colitis And Colitis Associated Cancer

In recent years, epidemiological studies have shown a significant increase of incidences regarding ulcerative colitis (UC) in most regions of the world. At present, a common therapeutic modality for inflammatory bowel disorders is the use of anti-inflammatory agents, including sulfasalazine and acetylsalicylic acid, steroid hormone, and other immunosuppressive agents. Most of these treatments are symptomatic and palliative because the etiology of the disease is not yet established. As a result of no proper drug available to treat UC, patients with UC are at a high risk of developing colitis-associated cancer (CAC). It is necessary to understand the genetic and molecular mechanisms involved in the pathogenesis of UC and CAC that lead to the path of new drug discoveries. Diagnostic and Treatment Methods for Ulcerative Colitis and Colitis-Associated Cancer provides innovative insights that describe the fundamental understanding of UC and CAC and the molecular mechanisms behind the etiology as well as modern diagnostic methods that are employed in UC and CAC. Current prevention and therapeutic strategies practiced in the pre-clinical level are also discussed. The content within this publication examines alternative medicine and dietary intervention and drug delivery techniques. It is designed for healthcare professionals, physicians, academicians, researchers, R&D organizations, and medical students involved in drug discovery and clinical and therapeutic research.

As in the first edition of Inflammatory Bowel Diseases this new edition continues to provide readers with a concise, yet in-depth review of many of the important areas in the history, epidemiology, pathogenesis, diagnosis, and treatment of the inflammatory bowel diseases (ulcerative colitis and Crohn's disease), as well as associated issues: extraintestinal manifestations, ostomy care, women's issues, economics, etc. This Second Edition provides the reders with up-to-date, state-of-the art approaches to these disease states, with expansion into the newer topics that have emerged in the past few years which include the expansion of biological agents for treatment, new studies in the epidemiology of IBD, the changing economics of IBD, breakthroughs in new endoscopic evaluations, major advances in novel radiographic techniques, the detection of colorectal cancer in patients with IBD and new findings in the genetics of IBD. New Trend / Developments (* These all emerged since our last edition) The most critical trend that has arisen over the past few years has been the introduction and expansion of biological agents in the treatment of inflammatory diseases worldwide. While only one agent, infliximab (Remicade), existed at the time of publication of my first edition, there have been multiple other agents either approved or pending approval for the treatments of these diseases, or in the upper-stages of development. The impact is not only upon the patients, but also on the health-care providers, policy makers, researchers, biotech and pharmacompanies, and the business community. Major changes worldwide in the epidemiology of IBD has spurred new studies in the demographics of who is getting these diseases and why. Previously characterized as diseases primarily affected Caucasians in industrialized countries, there has been an explosion of growth amongst the African American and Hispanic populations in the United States, and well as in pockets of these and other ethnic groups worldwide. The economics of IBD has been changing greatly, given the issues raised above, as well as major changes in the United States Medicare program, and other insurance changes. The growing proportion of the GNP that healthcare costs are consuming in the US and worldwide has shifted attention to decreasing utilization of health care services, and other cost-savings measures. Again, up to this point this has been an exclusive part of our IBD book. New findings in the genetics of IBD have been recently published. Our first edition had the finding of the first Crohn’s disease gene inserted just before going to press; so much has been published about the phenotypes and other genotypes that have emerged. Breakthroughs in new endoscopic evaluations of the bowel (ie. Capsule endoscopy, double-balloon enteroscopy, endoscopic ultrasound) and their use in the inflammatory bowel diseases will be a key highlight of this new book. Major advances in novel radiographic techniques employed in patients with inflammatory bowel disease (ie. CT enterography, MR enterography, advanced ultrasounds, etc.) will also an important component of our work. There have been numerous areas related to the development and detection of colorectal cancer in patients with IBD that have emerged in the past few years. Techniques of better detection (ie. Narrow band imaging; special mucosal staining; endoscopic histological evaluations) as well as research in the putative role of mesalamine and other agents for colorectal cancer prevention are all hot topics that will attract much interest from a variety of interest groups I described above. Identification of additional disease states that probably belong in the IBD family, such as microscopic colitis (including lymphocytic colitis), and collagenous colitis add to the diseases that will be discussed in this new edition.

Now published in two volumes to accommodate new chapters on the many advances in understanding and treatment options, this volume represents the definitive reference on inflammatory bowel disease, a spectrum of diseases that is receiving increasing attention as our understanding of the etiological factors increases and diagnostic tools are refined. Basic research accelerated at the beginning of this decade and is now yielding new, more targeted treatments than were available just a few years ago. Volume 1 is on IBD and Ulcerative Colitis, and Volume 2 is on IBD and Crohn's Disease. All areas that were covered in the second edition have been expanded and updated. New sections include one addressing etiology and pathophysiology of IBD, including environmental influences and effect of age at onset, and one with a focus on aggravating factors in the IBD patient such as infectious agents, non-steroidal anti-inflammatory drugs, and pregnancy.

Ulcerative colitis (UC) is a chronic inflammatory disease that affects the colon. According to the literature, some thirty percent of UC patients may require a subtotal colectomy and ileostomy due to failure of medical treatment, acute toxic colitis or dysplasia/cancer diagnosis. Some patients choose to get continence restored with either an ileorectal anastomosis (IRA) or an ileal pouch-anal anastomosis (IPAA). Worldwide most surgeons prefer an IPAA to an IRA, despite reports of pouchitis, impaired fertility and fecundity. Fear of recurring proctitis and fear of rectal cancer in the remaining rectum is contributing to the choice of an IPAA. Little is known regarding the outcomes of IRA compared with IPAA in UC patients. We aimed to investigate the anorectal function, quality of life (QoL), risk of failure and rectal cancer in patients with UC restored with IRA and IPAA respectively. Methods: Data about all Inflammatory bowel disease (IBD) patients was obtained from the Swedish National Patient Register (NPR) between 1964-2014 and in one study from the Linköping University Hospital medical records 2006-2012. Patients who developed cancer were identified from the Swedish National Cancer Register. We investigated the risk of cancer and inflammation, functional outcome and failure as well as the quality of life for IRA and IPAA patients. Investigation of risk for cancer in IRA and IPAA compared with the background population was performed using survival analytic techniques: uni-and multivariate regression, Kaplan Meier curves and standardized incidence ratio. Results: Twelve percent (7,889 /63,795) of UC patients required colectomy according to the NPR. The relative risk for rectal cancer among patients with an IRA was increased (SIR 8.7). However, the absolute risk was 1.8% after a mean follow up of 8.6 years and the cumulative risk 10- and 20-years after IRA was 1.6% and 5.6%, respectively. Risk factors for rectal cancer were primary sclerosing cholangitis in patients with an IRA (hazard ratio 6.12), and severe dysplasia or cancer of the colon prior to subtotal colectomy in patients with a diverted rectum in place (hazard ratio 3.67). Regarding IPAA, the relative risk to develop rectal cancer was (SIR 0.4) compared with the background population and the absolute risk was only 0.06% after a mean of 12.2 years of follow up. Among patients operated at the Linköping University Hospital: IRA patients reported better overall continence according to the Öresland score with in median3 (IQR 2–5) for IRA (n=38) and 10 (IQR 5–15) for IPAA (n=39, p<0.001). There were no major differences regarding the QoL. According to the NPR, after a median follow up of 12.4 years failure occurred in 265(32%) out of 1112 patients, of which 76 were secondarily reconstructed with an IPAA. Failure of the IPAA occurred in 103 (6%) patients with primary and in 6 (8%) patients after secondary IPAA (log-rank p=0.38). Conclusion: IRA is a safe restorative procedure for selected UC patients. Patients should be aware of the annual postoperative endoscopic evaluation with biopsies as well as the need to the use of local anti-inflammatory preparations. However, IRA should not be offered for UC patients with an associated primary sclerosing cholangitis diagnosis due to the increased risk to develop rectal cancer in their rectal mucosa. In such case, IPAA is probably the treatment of choice.

The latest edition of this text provides a comprehensive overview of the “natural flow of knowledge” regarding inflammatory bowel disease, with an emphasis on state-of-the art approaches that should be the basis for diagnosis and treatment of most patients. In addition to updated chapters, this volume includes new chapters on such topics as the impending biosimilar revolution, quality of care, and new challenges to previously held beliefs about IBD diagnosis, treatment, and pathogenesis. The book is also one of the first to have a chapter written specifically by and for physician extenders in the training of colleagues and the treatment of patients, which is of increasing importance moving forward in the medical profession. Written by experts in the field, Inflammatory Bowel Disease: Diagnosis and Therapeutics, Third Edition is a valuable resource for physicians, nurses, researchers, and other health care providers interested in the latest cutting-edge knowledge for treating patients with inflammatory bowel disease.

The diagnosis and treatment of commonly encountered bowel diseases, including diarrhea, irritable bowel syndrome, diverticular disease of the colon and rectal cancer are reviewed. Pharmacologic treatment is discussed in detail. The ACG guidelines for management of ulcerative colitis and Crohn's disease are included.

During the past decade, the medical and surgical treatment of ulcerative colitis has undergone dramatic advances, including the widespread use of immunomodulators, biological drugs, and restorative proctocolectomy. In order to correctly balance the risks and benefits of medical therapies and surgical procedures, there is a need for improved diagnosis of colonic disease, acute complications, extraintestinal manifestations, and early and delayed postoperative complications. Cross-sectional imaging techniques are therefore playing an increasing role in the assessment of ulcerative colitis and provide an essential complement to clinical data and endoscopy. This practical, illustrated volume on the role of cross-sectional imaging is aimed at radiologists, gastroenterologists, and surgeons who are engaged or interested in the diagnosis and care of patients with inflammatory bowel disease, particularly ulcerative colitis. After an overview of diagnostic imaging techniques, state-of-the-art assessment of colorectal inflammatory disease with CT colonography using water enema is discussed, followed by description of the plain radiographic and CT findings in patients with acute exacerbations and surgical complications. Subsequent chapters review the diagnostic findings and role of cross-sectional imaging in the assessment of sclerosing cholangitis (with emphasis on MR cholangiopancreatography), vascular complications (particularly portal and mesenteric thrombosis), associated neoplasms, such as colorectal cancer and abdominal desmoids, and perianal inflammatory disease. Normal postoperative appearances and early and delayed complications in patients treated with proctocolectomy and ileal pouch-anal anastomosis are also comprehensively reviewed.​

A clinical reference on the medical and surgical management of inflammatory bowel disease (IBD) in all age groups. Edited by a well known authority in the field and written by a group of 59 contributors from around the world, Inflammatory Bowel Disease is a major reference on this topic. Gastroenterologists, surgeons, internists, and family practitioners should be interested in this volume of the latest information on treatment and diagnosis as well as on the major new areas of research in the field.